Ann: Partnership provides funding for cutting-edge facility, page-29

Hi @Eqz, no expert on these things, but did do quite a bit of (very boring) reading on clinical reimbursement codes & posted that info.

I think @skyhigh2406 has explained it well. Previously Richard has stated US health insurance funds are very interested in PromarkerD & that code will also be necessary for billing to insurance. If you look at some of the bigger pathology labs like Labcorp & Quest, the patient’s tests are billed directly to their insurance company, not unlike Medicare bulk billing here.

Also whether there is potential here for PromarkerD to be covered by Medicare as a predictive screening tool, due to the billions spent on ESRD (dialysis & transplantation).

While being a complimentary diagnostic test to SLGT2 inhibitors (ie Janssen’s Invokana) would be the icing on the cake, PromarkerD is also very valuable as a stand alone test for predicting the development of kidney disease.

The US Govt has made all patients with ESRD eligible for Medicare cover in their recent bill on Chronic Kidney Disease & a focus on home dialysis. Not going to rehash all of that as we have discussed this extensively here in previous posts, but the collaborative working parties between US Govt, the medical profession & the National Kidney Foundation are ramping up standards of care for screening & treatment of early CKD/DKD to try & address this massive health burden (articles posted previously).

Have a great day all & hoping we may get some news soon.